Abstract:9584 Background: Lung carcinomas are most often diagnosed at stage IV, with metastases, which contribute to 90% of deaths of patients. Enormous efforts have been made in previous studies in seek of underlying mechanisms and treatments that prevent or cure metastases. However, few comprehensive conclusions have been drawn on organ-specific genomic landscapes and molecular dependencies of lung cancer metastases, largely due to limited sample sizes. Methods: We employed massive targeted next generation sequencing (NGS) with a panel covering 425 cancer-related genes on 10409 samples from 8619 patients with lung cancer, including 8479 from primary tumors and 1930 from metastases to the brain, liver, pleura, bones, and lymph nodes. We investigated single nucleotide variants (SNVs), copy number variants (CNVs), structural variations (SVs), mutational signatures, and other genomic characteristics at all primary and metastatic sites. With data of primary-metastatic tumor pairs, we also examined genomic evolutionary patterns. Results: Our data revealed that metastases harbored more instable and complicated genomes. Most SNVs (5/6), CNVs (41/47), and SVs (2/3) that showed significant differences of prevalence between primary tumors (PTs) and metastases (MTs) were MT-enriched. Among them, we identified a novel MT-enriched event, PTK2 amplification (2.33 folds), as well as known ones including mutations of TP53, ARID1A, and BRCA1 (1.23, 1.74, and 2.29 folds) , and amplifications of MYC, RICTOR, and EGFR (2.04, 2.15, and 1.59 folds). In addition, almost all actionable CNV alterations (6/7) showed higher frequencies in MTs. ALK fusions and EGFR mutations, which indicate distinct target therapies, exhibited opposite preference in MTs and PTs, respectively. We also identified MT site-specificity of alterations, such as NF2, TSC2, and LRP1B mutations enriched in the brain, BRAF and GNAS mutations absent in the liver, and APOBEC-associated mutational signatures enriched in lymph nodes. Moreover, we unraveled organ-specific patterns of genomic evolutionary trajectories in metastatic diseases. Conclusions: The genomic profile and evolutionary pattern of metastatic lung cancer differed from that of primary tumors. The identification of site-specific characteristics that may have empowered directional metastasis, such as NF2, TSC2, and LRP1B mutations in the brain and APOBEC-associated mutational signatures in lymph nodes, may guide personalized disease management, design of clinical trials, and/or discovery of therapeutic targets for metastatic lung cancer at different body regions.

Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma

Characterization of Evolution Trajectory and Immune Profiling of Brain Metastasis in Lung Adenocarcinoma

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

Mutational Signatures of Synchronous and Metachronous Brain Metastases from Lung Adenocarcinoma

Genetic Mutations Associated with Lung Cancer Metastasis to the Brain.

Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing

Genomic Alteration During Metastasis of Lung Adenocarcinoma

Whole-genome Sequencing of Matched Primary and Metastatic Hepatocellular Carcinomas

Genetic Characteristics of Lung Metastasis and Liver Metastasis from Left-Sided Colorectal Cancer with Microsatellite Stability.

Genomic Characterization of Metastatic Lung Cancers.

Genetic Heterogeneity Between Paired Primary and Brain Metastases in Lung Adenocarcinoma.

Genetic Differences Between Lung Metastases and Liver Metastases from Left-Sided Microsatellite Stable Colorectal Cancer: Next Generation Sequencing and Clinical Implications

Targeted Sequencing Reveals Distinct Pathogenic Variants in Chinese Patients with Lung Adenocarcinoma Brain Metastases.

Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma

P1.01-42 Whole-Exome Sequencing Identifies Novel Somatic Mutations Associated with Prognosis in Lung Cancer Metastatic to the Brain

Timing and Origins of Local and Distant Metastases in Lung Cancer

Mutational Characteristics of Bone Metastasis of Lung Cancer.

A Comparative Study of Genetic Profiles of Key Oncogenesis-Related Genes Between Primary Lesions and Matched Lymph Nodes Metastasis in Lung Cancer

Genetic Intratumor Heterogeneity Remodels the Immune Microenvironment and Induces Immune Evasion in Brain Metastasis of Lung Cancer.

Integrated Analyses of Multi-omic Data Derived from Paired Primary Lung Cancer and Brain Metastasis Reveals the Metabolic Vulnerability as a Novel Therapeutic Target

Molecular features of NSCLC patients with liver metastasis